SCHEMBL311346

SCHEMBL311346

CCN(CC)S(=O)(=O)N(Cc1ccccc1)c1ccc(C(=O)N2CCC(OCc3ccccc3)C2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.51
HPGD P15428 3/20 0.46
KMT2A Q03164 2/20 0.45
LMNA P02545 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HTT P42858 2/20 0.43
ALDH1A1 P00352 1/20 0.42
PDK1 Q15118 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
GRIN3A Q8TCU5 1/20 0.40
PKLR P30613 1/20 0.40
VNN1 O95497 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12017331 0.92 GAA (0.51) GAAHPGDKMT2ALMNASMN1; SMN2
SCHEMBL3287847 0.85 GAA (0.55) GAAHPGDKMT2ALMNASMN1; SMN2
SCHEMBL12442786 0.79 BCHE (0.52) KMT2ALMNASMN1; SMN2ALDH1A1GRIN2D
SCHEMBL12017289 0.76 GAA (0.55) GAAHPGDKMT2ALMNASMN1; SMN2
SCHEMBL306963 0.76 GAA (0.54) GAAHPGDKMT2ALMNASMN1; SMN2
SCHEMBL18426023 0.70 GRIN2D (0.52) SMN1; SMN2ALDH1A1GRIN2DGRIN3BGRIN1
SCHEMBL2525766 0.70 GRIN2D (0.52) SMN1; SMN2ALDH1A1GRIN2DGRIN3BGRIN1
SCHEMBL2526379 0.70 GRIN2D (0.52) SMN1; SMN2ALDH1A1GRIN2DGRIN3BGRIN1
SCHEMBL303273 0.70 HPGD (0.48) GAAHPGDKMT2ALMNASMN1; SMN2
SCHEMBL2977297 0.70 MEN1 (0.55) GAAKMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2012500834-A 2012-01-12 JP claimed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 GAA 3857/4885HPGD 3739/4885KMT2A 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.